Loading...

PerCP/Cyanine5.5 anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_PerCPCyanine55_CD45_Antibody_082418
C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (open histogram).
  • 30-F11_PerCPCyanine55_CD45_Antibody_082418
    C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (open histogram).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
103131 25 µg £60
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103132 100 µg £152
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Ramakrishna C, et al. 2019. Nat Commun. 10:2153. PubMed
  2. Zhang Q, et al. 2022. Nat Metab. 4:1055. PubMed
  3. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  4. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  5. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  6. Axelrod ML, et al. 2022. Nature. 611:818. PubMed
  7. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  8. Fei F, et al. 2022. Int J Mol Sci. 23:. PubMed
  9. Shi H, et al. 2022. Nutrients. 14:. PubMed
  10. Li J, et al. 2022. Elife. 11:. PubMed
  11. Matsuzawa M, et al. 2023. Nat Commun. 14:1417. PubMed
  12. Xiao Y, et al. 2023. EMBO J. 42:e111762. PubMed
  13. He Y, et al. 2023. Biomolecules. 13:. PubMed
  14. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  15. Doloff JC, et al. 2023. Sci Adv. 9:eade9488. PubMed
  16. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  17. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
  18. Daemen S, et al. 2021. Cell Reports. 34(2):108626. PubMed
  19. Zaman R, et al. 2021. Immunity. :. PubMed
  20. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  21. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  22. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  23. Xuan W, et al. 2022. Cancer Immunol Res. 10:770. PubMed
  24. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  25. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  26. Wu X, et al. 2022. J Clin Med. 11: . PubMed
  27. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  28. Poh AR, et al. 2022. Cell Rep. 41:111479. PubMed
  29. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  30. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  31. Lai C, et al. 2023. J Bone Miner Res. 38:86. PubMed
  32. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  33. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  34. Zha AH, et al. 2022. Lupus Sci Med. 9: . PubMed
  35. Guo J, et al. 2023. Cell Rep Med. 4:100881. PubMed
  36. Yang L, et al. 2023. Acta Pharmacol Sin. :. PubMed
  37. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  38. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  39. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  40. Khan NZ, et al. 2021. Brain Behav Immun. 92:165. PubMed
  41. Na E, et al. 2022. Am J Physiol Lung Cell Mol Physiol. 322:L550. PubMed
  42. Tang Y, et al. 2022. Dev Cell. 57:480. PubMed
  43. Li X, et al. 2022. Cell. 185:1709. PubMed
  44. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  45. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  46. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
  47. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  48. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  49. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  50. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  51. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  52. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  53. Padonou F, et al. 2022. EMBO Rep. 23:e53576. PubMed
  54. Golden GJ, et al. 2021. MBio. 12:e0118121. PubMed
  55. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  56. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
  57. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  58. Li Z, et al. 2021. Immunology. 163:105. PubMed
  59. Rodda LB et al. 2018. Immunity. 48(5):1014-1028 . PubMed
  60. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  61. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  62. Yang M, et al. 2020. Cell Prolif. 53:e12784. PubMed
  63. Browning D, et al. 2017. Gene Ther. 10.1038/gt.2016.88. PubMed
  64. Hanhai Z, et al. 2021. Aging (Albany NY). 13:13108. PubMed
  65. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  66. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  67. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  68. Garcia–Agudo LF, et al. 2019. FASEB J. :fj201900337R. PubMed
  69. Zaytseva D, et al. 2018. Physiol Rep. 6:e13812. PubMed
  70. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  71. Biffi G, et al. 2018. Cancer Discov. 2:282. PubMed
  72. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  73. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  74. Craver BM, et al. 2020. Blood Adv. 4:312. PubMed
  75. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  76. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  77. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  78. Zhong J, et al. 2018. Sci Adv. 4:eaas9864. PubMed
  79. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  80. Jeong D, et al. 2021. eLife. 0.416666666666667. PubMed
  81. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  82. Damal Villivalam S, et al. 2020. Nat Commun. 4313:11. PubMed
  83. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  84. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  85. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  86. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  87. Fernandez Garcia-Agudo L, et al. 2021. Cell Rep. 36:109548. PubMed
  88. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  89. Shen H, et al. 2022. Nat Commun. 13:6030. PubMed
  90. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  91. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
  92. Sakaguchi M, et al. 2022. Nat Commun. 13:6092. PubMed
  93. Chimenti I, et al. 2022. Cell Death Discov. 8:149. PubMed
  94. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  95. Vasilijevic J, et al. 2017. PLoS Pathog. 13:e1006650. PubMed
  96. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  97. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  98. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  99. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  100. Fleury M, et al. 2015. Development. 142: 3307 - 3320. PubMed
  101. Osborne JK, et al. 2021. Cell Reports. 36(3):109408. PubMed
  102. Wei SC, et al. 2020. Cancer Discov. . PubMed
  103. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  104. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  105. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
  106. Cong M, et al. 2021. Methods Mol Biol. 2388:59. PubMed
  107. Nicholas DA, et al. 2020. Scientific Reports. 10(1):13063. PubMed
  108. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  109. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  110. Frii J, et al. 2021. Immunity. 54(5):1002-1021.e10. PubMed
  111. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  112. Lee J, et al. 2022. Nat Commun. 13:1516. PubMed
  113. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  114. Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed
  115. Zhao J, et al. 2018. Stem Cell Reports. 10:180. PubMed
  116. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  117. Li N, et al. 2021. eLife. 10:00. PubMed
  118. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  119. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  120. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  121. Formaglio P, et al. 2021. Immunity. 54:2724. PubMed
  122. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  123. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  124. Adrover JM et al. 2019. Immunity. 50(2):390-402 . PubMed
  125. Christ A, et al. 2018. Cell. 172:162. PubMed
  126. Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed
  127. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  128. Hu Y, et al. 2021. Bioact Mater. 2905:6. PubMed
  129. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  130. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  131. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  132. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  133. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  134. Yang Z, et al. 2021. Sci Adv. 7:. PubMed
  135. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  136. Myerson JW, et al. 2021. Nat Nanotechnol. Online ahead of print. PubMed
  137. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  138. Du Q et al. 2019. Dev Cell. 49(4):618-631 . PubMed
  139. Branchett WJ, et al. 2020. Wellcome Open Research. 0.278472222. PubMed
  140. Liu Z, et al. 2015. Development. 142: 2452 - 2463. PubMed
  141. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  142. Sharma M, et al. 2020. Circ Res. 127:335. PubMed
  143. Shao M, et al. 2021. Cell Stem Cell. 28(4):685-701.e7. PubMed
  144. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  145. Krueger A, et al. 2022. Front Microbiol. 12:789042. PubMed
  146. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  147. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  148. Weinstock A, et al. 2021. Elife. :10. PubMed
  149. Joffin N, et al. 2021. Cell Stem Cell. 28(4):702-717.e8. PubMed
  150. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  151. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  152. Alonso-Herranz L, et al. 2020. Elife. 9:00. PubMed
  153. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  154. Timblin GA, et al. 2021. Nat Metab. 3:618. PubMed
  155. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  156. Lang V, et al. 2021. Elife. 10:. PubMed
  157. Toth K, et al. 2022. PLoS Biol. 20:e3001526. PubMed
  158. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  159. Li CJ, et al. 2018. J Clin Invest. 128:5251. PubMed
  160. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  161. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  162. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  163. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  164. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  165. Tuong ZK, et al. 2021. iScience. 24:103326. PubMed
  166. Thomas K, et al. 2022. JCI Insight. :. PubMed
  167. Xu X, et al. 2022. EMBO Rep. 23:e53509. PubMed
  168. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  169. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  170. Ngamsri KC, et al. 2020. Front Immunol. 11:407. PubMed
  171. Haider N, et al. 2020. Cell Commun Signal. 18:26. PubMed
  172. Bernstock JD, et al. 2019. J Allergy Clin Immunol. 145:358. PubMed
  173. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  174. Shan B, et al. 2020. Nat Metab. 1332:2. PubMed
  175. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  176. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  177. Xu G, et al. 2022. Front Pharmacol. 13:896601. PubMed
  178. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  179. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  180. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
  181. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  182. Calle P, et al. 2021. Cells. 10:. PubMed
  183. Klose A, et al. 2018. JCSM Rapid Commun. 9:20222. PubMed
  184. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  185. Chiang N, et al. 2019. J Clin Invest. 129:5294. PubMed
  186. Scott NA, et al. 2018. Front Immunol. 2.319444444. PubMed
  187. Upadhya R, et al. 2016. MBio. 7: 00547-16. PubMed
  188. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  189. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  190. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  191. Karolin A, et al. 2022. Front Pharmacol. 12:789080. PubMed
  192. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  193. Wong NR, et al. 2021. Immunity. 54:2072. PubMed
  194. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  195. Böhm AM et al. 2019. Dev Cell. 51(2):236-254 . PubMed
  196. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  197. Mesnieres M, et al. 2021. Cell Reports. 36(8):109618. PubMed
  198. Doss PMIA, et al. 2021. Cell Reports. 34(10):108833. PubMed
  199. Caporarello N, et al. 2020. Aging Cell. 19:e13196. PubMed
  200. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  201. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  202. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  203. Sánchez-del-Campo L, et al. 2021. J Exp Clin Cancer Res. 40:117. PubMed
  204. Steele NG, et al. 2021. Clin Cancer Res. 27:2023. PubMed
  205. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  206. Baron CS, et al. 2018. Nat Commun. 9:2517. PubMed
  207. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  208. Miragaia RJ, et al. 2018. Sci Rep. 8:685. PubMed
  209. Patel K, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.11. PubMed
  210. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  211. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  212. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  213. Chung S, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L921:318. PubMed
  214. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  215. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  216. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  217. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  218. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  219. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  220. Sharma M, et al. 2019. Immunometabolism. 1. PubMed
  221. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  222. Liu SS, et al. 2021. Immunity. :. PubMed
  223. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  224. Gao P, et al. 2020. Front Immunol. 1.636111111. PubMed
  225. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  226. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  227. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  228. Durga Devi T, et al. 2017. Am J Pathol. 187:2659. PubMed
  229. Wang L, et al. 2020. Nat Commun. 0.654166667. PubMed
  230. Garcia-Alegria E, et al. 2016. Sci Rep. 6: 25917. PubMed
  231. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  232. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  233. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  234. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  235. Caporarello N, et al. 2022. Nat Commun. 13:4170. PubMed
  236. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  237. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
  238. Han Y, et al. 2019. J Clin Invest. 130:26. PubMed
  239. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  240. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
  241. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  242. Uematsu T, et al. 2015. Sci Rep. 5: 17577. PubMed
  243. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  244. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  245. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  246. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  247. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  248. Sheriff L, et al. 2020. Dis Model Mech. 13:dmm046383. PubMed
  249. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
RRID
AB_893340 (BioLegend Cat. No. 103131)
AB_893340 (BioLegend Cat. No. 103132)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV395™ anti-mouse CD45 30-F11 FC
Go To Top Version: 3    Revision Date: 08/24/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account